Radius Health v. Orbicular: Plaintiffs Win Tymlos® ANDA Patent Battle

In a decisive victory for branded pharmaceutical patent protection, the Massachusetts District Court entered final judgment on August 13, 2025, in favor of Radius Health, Inc. and Ipsen Pharma S.A.S. against Orbicular Pharmaceutical Technologies Private Limited, blocking generic entry for Tymlos® (abaloparatide) until at least April 30, 2038. Case No. 1:22-cv-11546 centered on five patents covering the bone-loss treatment used for postmenopausal osteoporosis, with Orbicular’s ANDA filing triggering one of pharmaceutical patent litigation’s most high-stakes mechanisms — the Hatch-Waxman Act’s Paragraph IV certification process.

The outcome is significant across multiple dimensions: a stipulated infringement agreement, a partial summary judgment win, a ten-day bench trial, and a nuanced final ruling that invalidated two patent claims while upholding nine others. For pharmaceutical patent attorneys, ANDA litigators, and R&D teams monitoring biosimilar and generic entry strategies, this case offers a rich playbook of procedural milestones, validity challenges, and strategic outcomes.

Case Overview

The Parties

The Patents at Issue

Five U.S. patents were asserted, covering formulations, compositions, and delivery systems related to abaloparatide:

• • RE49,444 — Reissue patent covering abaloparatide formulations
• • US8,148,333 — Covering peptide compositions
• • US8,748,382 — Formulation and delivery claims
• • US10,996,208 — Manufacturing and composition claims
• • US11,782,041 — Later-filed claims covering the abaloparatide delivery system

Legal Representation

Plaintiffs were represented by Choate, Hall & Stewart LLP, with lead attorney Eric J. Marandett. Defendant fielded a six-attorney defense team from Harbor Law Group and Windels Marx Lane & Mittendorf, LLP, including Alan H. Pollack, Louis H. Weinstein, Jason Aaron Lief, and others — signaling the litigation’s complexity and Orbicular’s commitment to a full validity challenge.

Litigation Timeline & Procedural History

Filed on September 20, 2022, in the District of Massachusetts — a common and strategically significant venue for pharmaceutical ANDA litigation — the case ran approximately 34 months to final judgment on August 13, 2025, under Chief Judge Richard G. Stearns.

Key milestones shaped the litigation’s trajectory:

• March 12, 2024: The parties executed a Stipulation of Infringement, in which Orbicular conceded that commercial activities related to the ANDA Product would infringe claims 20, 34, and 57 of the ‘444 patent; claim 7 of the ‘382 patent; and claims 6 and 12 of the ‘041 patent — a strategically significant concession that narrowed the trial’s scope exclusively to validity.
• November 27, 2024: The Court issued a Memorandum and Order on Cross-Motions for Summary Judgment, finding that the ANDA Product would additionally infringe claims 14 and 15 of the ‘208 patent and claim 13 of the ‘333 patent.
• March 17 – April 2, 2025: A ten-day bench trial addressed remaining disputed patent validity questions.
• July 30, 2025: The Court issued its Findings of Fact, Rulings of Law, and Order After Bench Trial.
• August 13, 2025: Final Judgment entered.

The Verdict & Legal Analysis

Outcome

The Court entered final judgment substantially in favor of Plaintiffs. Nine asserted patent claims across five patents were upheld as valid and infringed. Orbicular succeeded on only a narrow portion of its invalidity challenge — claims 2 and 11 of the ‘333 patent were found invalid by clear and convincing evidence. No damages were awarded (consistent with Hatch-Waxman ANDA practice), but the Court imposed the most consequential remedy available under 35 U.S.C. § 271(e)(4)(A): ANDA approval is blocked until no earlier than April 30, 2038, the last expiration date among the patents-in-suit.

Verdict Cause Analysis

The litigation resolved across three distinct procedural pathways, each instructive:

1. Stipulated Infringement (March 2024): Orbicular’s decision to stipulate infringement on six claims — rather than contest them at trial — was a calculated resource allocation. By conceding infringement early, the defense concentrated entirely on invalidity arguments at trial. This is a recognized ANDA litigation strategy, particularly when formulation or composition claims closely mirror the accused product’s specifications. However, it simultaneously stripped the defendant of any non-infringement fallback position.

2. Summary Judgment Infringement Findings: The Court’s November 2024 ruling resolved two additional patents’ infringement questions pretrial, further limiting trial scope. For practitioners, this underscores the value of pre-trial motion practice in ANDA cases to eliminate contested issues before costly bench trials.

3. Bench Trial Validity Challenge: The ten-day trial focused entirely on whether Orbicular could invalidate the remaining claims by clear and convincing evidence — the demanding statutory standard under 35 U.S.C. § 282. Orbicular succeeded only on claims 2 and 11 of the ‘333 patent. The Court’s findings suggest that Orbicular’s invalidity arguments (likely grounded in obviousness and/or anticipation) were insufficient across the broader patent portfolio, despite what was evidently a thorough evidentiary presentation.

Legal Significance

Several aspects carry precedential and strategic weight for pharmaceutical patent litigation:

• Reissue Patent Survival: The ‘444 reissue patent (RE49,444) survived validity challenge on three asserted claims. Reissue patents often face heightened scrutiny, making this outcome relevant for patentees pursuing reissue strategies to broaden or clarify original claims.
• Multi-Patent Portfolio Defense: Plaintiffs’ assertion of five patents with overlapping expiration dates exemplifies effective patent lifecycle management — even if one or two patents are invalidated, the remaining portfolio can sustain injunctive relief.
• Partial Invalidity Without Disrupting the Injunction: Orbicular’s limited success (invalidating two ‘333 patent claims) was insufficient to affect the ultimate market exclusivity order, demonstrating that partial invalidity victories can be strategically hollow when a robust portfolio remains.

Strategic Takeaways

For Patent Holders: Layered portfolio strategies in pharmaceutical litigation — asserting multiple patents with staggered expiration dates — create redundancy that survives partial invalidity challenges. Reissue proceedings can be a valuable tool to strengthen vulnerable claim sets.

For Generic Manufacturers/ANDA Filers: Early stipulation of infringement focuses resources but eliminates flexibility. Prior art searches and IPR petitions at the USPTO should be exhausted before conceding infringement on core claims. An IPR parallel track, if viable, may create stronger leverage.

For R&D Teams: The April 2038 ANDA exclusion signals that freedom-to-operate analyses for abaloparatide formulations must account for a broad, multi-patent estate. Any new delivery mechanism or formulation variant must be evaluated against the surviving claim landscape.

Industry & Competitive Implications

The Tymlos® ruling reinforces a broader trend in branded pharmaceutical ANDA litigation: well-constructed patent portfolios combining composition, formulation, and method-of-use claims across multiple patent families represent a durable barrier to generic entry. For the osteoporosis therapeutics market — already competitive with teriparatide (Forteo) and romosozumab (Evenity) — the effective delay of generic abaloparatide until 2038 sustains Radius Health’s and Ipsen’s market positioning for over a decade.

For the generic pharmaceutical industry, the case illustrates the elevated evidentiary burden of invalidity challenges at trial. Despite fielding a six-attorney defense team with two law firms, Orbicular’s validity case succeeded only partially — a reminder that clear and convincing evidence is a demanding standard, particularly for later-filed pharmaceutical patents supported by robust prosecution histories.

Licensing implications are also notable. With generic entry foreclosed until 2038, third-party manufacturers seeking access to abaloparatide-related technology will likely need to engage in licensing negotiations with Radius Health and Ipsen — reinforcing the commercial value of the surviving patent estate.